Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice.
about
Leishmania carbon metabolism in the macrophage phagolysosome- feast or famine?A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous LeishmaniasisIn vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animalsA new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imagingBioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sicknessActivity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screeningLuciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitroIdentification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model systemNon-invasive in vivo study of the Trypanosoma vivax infectious process consolidates the brain commitment in late infectionsAppraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasisHighly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferaseInfrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasisFitness of Leishmania donovani parasites resistant to drug combinationsPathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB)Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesOptimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.Interleukin 32γ (IL-32γ) is highly expressed in cutaneous and mucosal lesions of American Tegumentary Leishmaniasis patients: association with tumor necrosis factor (TNF) and IL-10.Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity.Functional analysis of Leishmania cyclopropane fatty acid synthetaseA novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.Establishment of ATP-based luciferase viability assay in 96-well plate for Trypanosoma congolense.Noninvasive biophotonic imaging for studies of infectious disease.Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling.Rapid in vitro protein synthesis pipeline: a promising tool for cost-effective protein array design.Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs.In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery.Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation.Advances in the use of genetically engineered parasites to study immunity to Toxoplasma gondii.An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.Transgenic Leishmania and the immune response to infectionExperimental infection of Phlebotomus perniciosus by bioluminescent Leishmania infantum using murine model and artificial feederImaging of the host/parasite interplay in cutaneous leishmaniasis.Visceral leishmaniasis: experimental models for drug discovery.Leishmania-host interactions: what has imaging taught us?Bioluminescence imaging: a shining future for cardiac regeneration.Optical molecular imaging in drug discovery and clinical development.Imaging host-Leishmania interactions: significance in visceral leishmaniasis.Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?Reporter systems for in vivo tracking of lactic acid bacteria in animal model studies.
P2860
Q26776497-5EE6CB8A-73D5-4AC2-B2EB-6E6127C6153DQ26786195-D256D0E5-8ED1-4A4B-8FE9-EB7076CDD05EQ27006069-4A588D55-AB6C-4CEC-B947-F0DF16C068D1Q27011506-0BBDF35D-F848-4D4C-8FBF-DC940F8415C8Q28475768-36F1E260-5E26-4F1B-A704-8966BACB387CQ28476774-9A4B633E-B67B-4C1D-88F9-17907A09B7BAQ28477052-2D066A91-4912-4906-9311-DE51E80846A6Q28477163-0CDA3DEC-4B5E-4F39-B260-5EB5068CA3CDQ28484843-6256896B-F6B2-40A5-B28E-0052F0F8E39EQ28485377-29DC330B-A0D3-4D11-8A3E-8F97A101B889Q28535374-45033720-85B7-4A3B-92E0-D58AD5D8366DQ28545229-B43F3C20-0C6B-496F-9FB2-F45F7EE425CCQ28545794-1D08B18C-726D-4FE1-815E-28BFCD9AE19AQ28550034-01E99B1D-EAAF-474E-B795-518AA2E2A981Q30488470-7D5074FF-9EAB-40A8-9300-420AFBBD83DFQ33308750-57885E46-6A79-446D-95FC-C737BAB0647AQ33633481-E864E3FA-09A9-4B22-B2DF-5E6D6305A65DQ33676413-1ECA8F8E-FC3F-423B-9316-34DFC6756154Q34516403-7A313656-54CD-40B9-8E1B-5B1E21FEBF0AQ34669706-316FB206-0CC4-476D-99CE-9D16CD34B13CQ34749735-67B68FD1-D4A2-4FD6-AE51-59A6F20DCBCCQ34886067-4B521F91-FE12-4705-9607-9B23968E3454Q35122993-D2F96738-B7C7-4986-9043-70CC5FE78550Q35136080-A0118347-113E-457A-8B8F-87AACADFEAF5Q35635939-07F24B8D-CDD4-423E-96D2-9096C1FE7E38Q36050879-46F8AABD-1697-4550-83C7-0FAC8DF98BF9Q36994297-87D035D1-9DFC-4883-B647-9081922567D9Q37020701-267BE3A9-26B0-433C-ACD3-C0C5A54CF3FCQ37056732-50D0B2CD-C48F-4787-B089-3A33F4C2E264Q37069597-9B946527-1B5D-4D29-8866-3521E8DDDF9CQ37081691-FFFDF377-0291-4E72-AB50-2CD3E8A16464Q37167717-868B78DC-8841-4F91-9661-0CEC0F553E51Q37760628-034BA04F-576D-4307-81DB-0EE677EE677DQ37842069-A4148395-840F-48B9-B60C-65D538D6C67EQ37912265-1C84EC30-211C-4C51-8D63-BBB766EFF0D8Q38080896-6CB108FD-C23B-456B-BA74-DE7AD5906765Q38089835-4230FC0D-9153-4B89-AF0C-87B055168938Q38114928-0F807DA9-4B6A-410C-A603-7513C9563BB1Q38188571-FF078F7C-0CA3-4B86-A1C1-1D13C99411BEQ38620150-520DF2C4-A266-47D6-93F0-68EB50B9CE24
P2860
Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Bioluminescent Leishmania expr ...... itism features in living mice.
@en
Bioluminescent Leishmania expr ...... itism features in living mice.
@nl
type
label
Bioluminescent Leishmania expr ...... itism features in living mice.
@en
Bioluminescent Leishmania expr ...... itism features in living mice.
@nl
prefLabel
Bioluminescent Leishmania expr ...... itism features in living mice.
@en
Bioluminescent Leishmania expr ...... itism features in living mice.
@nl
P2860
P1476
Bioluminescent Leishmania expr ...... itism features in living mice.
@en
P2093
Geneviève Milon
Mai Lebastard
P2860
P304
P356
10.1111/J.1462-5822.2004.00468.X
P577
2005-03-01T00:00:00Z